Clinical Trials Browser

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03660826 2026-06-02

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Phase 2 Active not recruiting

288 enrolled 21 charts

Sarcoma

Carcinosarcoma, Carcinoma, Endometrioid

NCT05112601 2026-04-21

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Phase 2 Recruiting

81 enrolled

Gynecologic

Endometrial Neoplasms, Carcinoma, Endometrioid

NCT02598219 2026-03-18

SENTIRAD

Phase 3 Active not recruiting

262 enrolled

Carcinoma, Endometrioid

NCT03875820 2026-03-10

FRAME

Phase 1 Active not recruiting

87 enrolled

Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Endometrioid

NCT04065269 2026-02-20

ATARI

Phase 2 Active not recruiting

174 enrolled

GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT06463028 2025-12-24

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Phase 2 Recruiting

40 enrolled

Gynecologic

Genital Diseases, Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT01935934 2025-10-01

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Phase 2 Completed

102 enrolled 14 charts

Carcinoma, Endometrioid

NCT03748186 2025-08-20

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Phase 1 Completed

136 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT04458597 2025-08-01

Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.

Phase NA Completed

23 enrolled

Sarcoma

Carcinosarcoma, Adenocarcinoma, Clear Cell, Carcinoma, Endometrioid, Cystadenocarcinoma, Serous

NCT06549855 2024-08-12

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Phase NA Not yet recruiting

10 enrolled

Gynecologic

Turcot syndrome, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT05001282 2024-08-07

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Phase 1/2 Terminated

79 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Fallopian Tube Neoplasms, Krukenberg Tumor, Ovarian Diseases, Ovarian Neoplasms, Recurrence, Uterine Diseases, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT06468215 2024-07-16

Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

Phase NA Not yet recruiting

16 enrolled

GynecologicLymphoid

Lymphoma, Follicular, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT05080556 2024-04-12

ACTOv

Phase 2 Recruiting

80 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Carcinoma, Endometrioid

NCT03345784 2024-02-20

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

Phase 1 Terminated

10 enrolled 15 charts

Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms, Carcinoma, Endometrioid

NCT05945407 2023-07-14

Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer

Phase NA Recruiting

57 enrolled

Gynecologic

Endometrial Neoplasms, Carcinoma, Endometrioid

NCT03824704 2023-06-12

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

Phase 2 Terminated

1 enrolled 7 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Carcinoma, Endometrioid

NCT02728258 2022-02-15

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Phase 2 Completed

11 enrolled 12 charts

Carcinoma, Endometrioid

NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Phase 1 Withdrawn

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

NCT02093598 2020-11-27

POEM

Phase 2 Completed

10 enrolled

Carcinoma, Endometrioid

NCT01440998 2018-04-05

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Phase 1 Completed

18 enrolled

Carcinoma, Endometrioid

Clinical Trials

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

SENTIRAD

FRAME

ATARI

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

ACTOv

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

POEM

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer